using Dulbecco's modified Eagle's medium supplemented with 2-mercaptoethanol (10 -5 M, final concentration), sodium pyruvate (0.11 g/liter) L-asparagine (0.036 g/liter), penicillin (100 U/mi), streptomycin (100 #g/ml) and 10% fetal calf serum (FCS); or in Click's medium (21) supplemented with penicillin, streptomycin, and 10% FCS at 2% CO2, without rocking.
Polyclonal and Antigen-specific In Vitro Activation of Human Lymphocytes. For polyclonal activation, 1.5 × 106 human PBL were cultured in l-mi flat-bottom wells (Nunc GmbH, Wiesbaden, FRG) together with pokeweed mitogen (PWM) in a 1:200 final dilution of the stock solution (Gibco Laboratories, Grand Island, NY). Some experiments were carried out with cryopreserved human PBL. Previous cryopreservation did not alter the yield of antibodies produced in culture, nor the B cell frequencies determined by limiting dilution (F. Emmrich, unpublished observation). Antigen-specific activation was achieved by incubating 2 × 105 unseparated PBL per well together with heat-killed, pepsin-cleaved Strep A in 200-#1 round-bottom microtiter wells (Nunc GmbH). The microorganisms were titrated as indicated. Culture supernatants were tested by solid-phase ELISA for various antibodies produced during the culture period. Antibodies appear in measurable amounts generally on day 4 and reach a plateau between days 8 and 12. By the cell separation procedure described above, no carry over of cytophilic Ig was observed that exceeded our sensitivity threshold of 100 pg/ml. Culture SUP harvested at day 12 by centrifugation were stored at -20 °C in microtiter plates until assay.
Antibody Assays. Solid-phase ELISA were performed essentially as described (19) for the determination of anti-A-CHO antibodies as well as for the determination of total IgM and IgG in cell culture SUP. Human IgM anti-A-CHO or IgG anti-A-CHO reference preparations of a human serum pool (10 sera of healthy blood donors) were diluted in culture medium, and a seven-point duplicate standard dilution curve, ranging from 0.26 to 4,000 ng/mi, was set up on each assay plate. In general, plates were measured after 30 rain, 2 h, and 24 h by an automatic photometer (MR-580; Dynatech Laboratories, Inc., Alexandria, VA) in order to find high as well as low test values in sensitive regions of the shifting standard curve. Standard curves were calculated and drawn by an Applesoft BASIC program (SPLINE 4) which uses spline functions to find an optimal nonlinear standard curve for calculating Ig concentrations.
For inhibition studies, soluble carbohydrates or monosaccharides were added in various concentrations, as indicated in Fig. 1 , to culture SUP containing anti-A-CHO antibodies, or to purified reference antibodies, before incubation of antigen-coated microtiter plates.
Determination of B Cell Precursor Frequencies. B cell precursor frequencies for IgM or
IgM anti-A-CHO-producing cells were determined by limiting-dilution analysis of replicate microcultures. Varying numbers of AET-rosette-negative cells in log~ dilution steps were cultured on 105 unseparated or T cell-enriched PBL irradiated with 3,000 rad in 96-well round-bottom microtiter plates in a final volume of 0.2 ml Click's medium with 10% FCS containing PWM (1:200) as polyclonal activator. 20 replicate cultures were established for each dose of B cells, ranging from 2 × 105 to 40 cells in the experiments 5 5 described. In culture wells with 2 × 10 and 1 × 10 cells, the amount of feeder cells was reduced to 5 × 104. As mentioned above, the rosette-negative population includes 30-50% non-B cells, so that the determined B cell frequencies are underestimated up to 100%. For control, five wells with no added B cells and five wells with 2 × 104 irradiated B cells were included in each culture plate, containing, in general, three culture groups. After 12 d the culture SUP were harvested and stored until antibody assay. Those wells with more Ig than the arithmetic mean plus three standard deviations of the controls were scored as "positive", and the fraction of negative wells was calculated for each B cell dose.
Poisson analysis was used to determine the precursor frequency for Ig-producing cells (for theory, see reference 22) by plotting the number of cells against the proportion of negative wells within each test group. Frequencies were calculated by an iterative program (MINCHI), written in Applesoft, which provides four mathematically different fitting approaches. The minimum X 2 method was selected according to Taswell (23) , considering his criteria that beside P > 0.05, the frequency determined by minimum X 2 should stay within 4-15% of that determined by the maximum likelihood method. 
Results

Quantities of Total IgM and IgG, and of A-CHO-specific lgM and IgG Produced In Vivo and by Polyclonal Activation In Vitro.
We studied seven randomly chosen healthy adults in these experiments, as well as one donor (MSS) specially selected because of a major GIcNAc-binding antibody spectrotype in his serum (12) . We determined IgM and IgG concentrations by radial immunodiffusion, whereas we measured IgM anti-A-CHO and IgG anti-A-CHO concentrations by a solidphase ELISA. For comparison, PBL of these donors were stimulated in vitro by PWM, and after 12 d, total Ig and specific Ig were measured in the cell culture, also by solid-phase ELISA. A compilation of these results appears in Table I . We prepared the reference antibodies used as standards for the ELISA assay from a pool of 10 human sera; they represent average avidity spectra as judged by comparing their binding curves with that of individual antibody preparations (data not shown). Strikingly high proportions of total IgM and IgG of all donors bound to A-CHO, ranging from 1.0 to 13.1% for IgM anti-A-CHO and from 0.5 to 9.5% for IgG anti-A-CHO in serum. In culture SUP, we found high proportions of anti-A-CHO (0.5-29%) for IgM but not for IgG (0.07-0.6%) Fine specificity analysis ofanti-A-CHO produced after polyclonal B cell activation in vitro (A) compared with affinity-purified anti-GlcNAc IgM adjusted in culture medium to the same antibody concentration (B). IgM anti-A-CHO was measured by a solid-phase ELISA using stearoyI-A-CHO as antigen, and an enzyme-labeled anti-human IgM as detection reagent.
( Table I ), The ratio of IgM anti-A-CHO to IgG anti-A-CHO ranged from 0.1 (donor HZO) to 3.3 (donor CMR) in serum, whereas, in strong contrast, in vitro polyclonally activated PBL produced mainly IgM anti-A-CHO with IgM/IgG ratios of 8 (JEN) and 397 (CMR) to one. The deficiency in IgG anti-A-CHO production was not a consequence of a deficiency in the total IgG production in vitro, because total IgM/IgG ratios were, in most cases, only slightly lower than in serum.
Fine Specificity of Anti-A-CHO Antibodies Produced In Vitro. A-CHO-specific
antibodies in sera of immunized animals (24) or of human donors (7) consist mainly of antibodies to GIcNAc, the immunodominant group of the A-CHO. To analyze the fine specificity of anti-A-CHO antibodies produced in vitro we used various mono-and polysaccharides. They were tested for their ability to inhibit the binding to solid-phase A-CHO of anti-A-CHO antibodies in culture SUP of polyclonally activated PBL (Fig. 1 ). This was compared with the affinity-purified IgM anti-GlcNAc preparation from the serum of the same individual, after adjusting to a similar Ig concentration as the antibody produced in vitro. A-CHO and its monosaccharide hapten GicNAc inhibited both antibody populations, whereas we saw no inhibition with the carbohydrate of C-streptococci (C-CHO), which carries N-acetyl-D-galactosamine (GalNAc) disaccharide side chains instead of GIcNAc on the same rhamnose backbone (13) . As usual, inhibitions with the monosaccharides required higher inhibitor concentrations than with the complete carbohydrate molecule. From these results, we conclude that, similar to antibodies produced in vivo, most anti-A-CHO antibodies produced in vitro are directed to GIcNAc.
Determination of B Cell Precursor Frequencies for IgM and IgM Anti-A-CHO.
To study whether the high proportions of A-CHO-specific IgM in vivo and in vitro were reflected in PBL with an equally high proportion of B cells of the same specificity, we did the following experiments. We determined the frequencies of IgM-producing B cells and the frequencies of B cells that produce IgM anti- A-CHO by limiting dilution analyses using B cell-enriched PBL. We chose three donors (MSS, HTA, JEN) with high, intermediate, and low proportions, respectively, of IgM anti-A-CHO antibodies after polyclonal activation in macrocultures (see Table I ). Fig. 2 shows a representative experiment. By plotting cell numbers versus the log of the fraction of negative cultures, we obtained straight lines in all cases, demonstrating single-hit kinetics, which allows the calculation of precursor frequencies (22) . All frequencies are minimum estimates because of the contamination by non-B cells. In order to obtain correct ratios, we adjusted the detection limits of the assays (used for both IgM and IgM anti-A-CHO) to equivalent sensitivities. Proportions of IgM anti-A-CHO-specific B cells (absolute frequencies) were calculated by dividing their precursor frequencies by that of IgM-producing cells. Table I . I Percentages calculated from serum lg concentrations given in Table I . Table II , representing the highest (1:173) and lowest (1:4272) frequency of IgM-producing cells. This pronounced experimental variability is primarily due to variation in the efficiency of PWM activation. In spite of this variability, we found the same absolute frequencies of IgM anti-A-CHO-producing B cells in the experiments with the lowest and highest efficiency of mitogen activation.
In agreement with other groups, <1% of all human peripheral blood B cells are activated by PWM (25, 26) , in contrast to mouse B cells, of which 30% may be activated polyclonally (27) . In view of the low percentages of B cells activated by PWM, and the high proportion of A-CHO-specific B cells among them, we suspected that PWM preferentially stimulated A-CHO-specific B cells. We determined IgM anti-A-CHO/total IgM ratios, using different polyclonal activation conditions. We had previously found that, under Mishell-Dutton conditions at high cell densities (106 cells per round-bottom microtiter well), spontaneous polyclonal activation occurs, resulting in IgM production >20-fold greater than that of the same number of PBL cultured in the same volume, with the same FCS, in fiat-bottom wells. PWM does not substantially increase IgM production when added to such high-density cultures. For cells from donor MSS, the proportions of IgM produced by high-density activation that had specificity to A-CHO ranged from 6.2 to 33.3% (mean, 15.8%) in six independent cultures, and thus are similar to the data shown in Table II for PWM activation of PBL from MSS. Preferential PWM activation of IgM anti-A-CHO-producing B cells is therefore unlikely. However, in cultures without antigen or mitogen, at low cell densities, the proportion of IgM anti-A-CHO is very much smaller than in cultures with either high density, or mitogen-or antigen-induced activation. This is shown in Table III for donor MSS, and in the control cultures of Table IV for donor CMR. We think that under these in vitro conditions, only those B cells that had been preactivated in vivo by unknown antigens secrete IgM. Alternatively, B cells specific for FCS components might be preferentially stimulated under these culture conditions. We also considered the remote possibility that A-CHO binding occurs via the constant part of IgM, particularly in the case of donor MSS whose IgM contained 15% A-CHO-binding antibodies. However, using Fab' fragments of affinitypurified IgM anti-GicNAc antibodies from that donor, we found binding to solid-phase A-CHO at levels similar to those seen with the complete molecule. Both antibody preparations bound specifically to A-CHO only, and not to the closely related carbohydrate of group C streptococci (data not shown).
Induction of a Specific In Vitro Response to Strep A Carbohydrate.
Among a variety of culture systems, we found that the original Mishetl-Dutton procedure (20) with Mishell-Dutton medium, rocking platform, and the special gas mixture (10% CO2, 7% 02, 83% N2), and the Click's system (21), provided adequate conditions for the specific induction of anti-A-CHO antibodies. Specific responses could be induced only by the bacterial particles, and not by the soluble A-carbohydrate (data not shown). Fig. 3 shows IgM anti-A-CHO antibody concentrations among PBL from five donors, stimulated by various doses of Strep A vaccine. Only in these donors (CMR, MSS, and HTA) could anti-A-CHO antibody secretion be enhanced, with a peak response at 2 × 10 ~ to 2 × 104 streptococcal particles per microculture. It should be noted that values of individual culture wells varied far more than observed in PWM-stimulated cultures. This may indicate that, for specific activation, spatial relationships between cooperating cells might be important. In some donors, especially in donor MSS, IgM anti-A-CHO antibodies were spontaneously produced to a considerable extent. This phenomenon was not caused by cytophilic antibodies, because cultures harvested immediately after being established were consistently negative for anti-A-CHO antibodies. To demonstrate that the increase of anti-A-CHO antibodies was not a part of a polyclonal increase in total IgM, we performed the experiment shown in Table  IV Discussion In recent studies on quantitative determinations of total anti-A-CHO antibodies in human sera (in which no distinction was made between IgM and IgG), concentrations of 20-250 gg/ml anti-A-CHO were reported for 30 randomly selected healthy donors (28) . In contrast, in a group of 12 patients suffering from acute rheumatic fever, 70-660 #g/ml anti-A-CHO (29) were found. These studies used anti-A-CHO from hyperimmunized rabbits as reference antibody for quantitative determinations, measured in a fluid-phase radioimmunoassay. Because of a possibly higher average affinity of the oligoclonal rabbit antibodies, and because low-affinity human antibodies might be missed in the fluid-phase assay, the serum concentrations of anti-A-CHO, which are presumably of low average affinity, might have been underestimated in those studies. This might also explain why no IgM anti-A-CHO could be detected in human sera in a previously published survey (7) .
To circumvent these problems, we used human IgM and IgG that had been taken from pooled serum and affinity-purified on A-CHO columns as reference for solid-phase ELISA measurement of specific antibodies. In eight healthy donors we found 26-837 #g/ml total anti-A-CHO. The accuracy of the results was confirmed by independent experiments. For instance, we could elute amounts of anti-A-CHO from A-CHO affinity columns as were predicted from serum determinations. This eluant was immunoelectrophoreticaily pure IgM and IgG (data not shown). Furthermore, for IgM, the proportions of anti-A-CHO in serum titers were reflected in the proportions of precursor B cells found in limiting dilution analyses (Table II) . Therefore, proportions of A-CHO-specific antibodies comprising >10% of the total IgM or IgG appear not to be unusual even in healthy human individuals without a history of anamnestic rheumatic fever or frequent tonsillitis.
These antibodies are mainly of GIcNAc specificity and are restricted predominantly to the IgG2/K isotype (7). Anti-GlcNAc antibodies may have been induced not only by A-CHO, but also by other bacterial polysaccharides containing terminal GIcNAc moieties in a 1,3-glycosidic linkage, such as the O substance of gram-negative bacteria (30) . Moreover, terminal GIcNAc is exposed transiently during synthesis or degradation of blood group substance (P. Hanfland, personal communication) and might act as an antigenic stimulus. We think, however, that the functional significance of the large amounts of anti-GicNAc antibodies in healthy individuals lies in the persistance of streptococci in human tonsils without any symptoms of tonsillitis. It is possible that the immune system prevents an overgrowth of these bacteria by maintaining a potent state of natural immunity. Varying antibody levels in individual donors may be due to genetic control, as demonstrated for rabbit (31, 32) and mice (33) , as well as different levels of continuous challenge by the bacteria.
All human adults seem to be primed to Strep A, as revealed by an analysis of sera from -200 healthy blood donors that contained IgM anti-A-CHO in varying amounts. Two cord-blood sera, on the other hand, showed a total lack of IgM anti-A-CHO, while containing IgG anti-A-CHO, presumably from the mother. In addition, we could not induce IgM anti-A-CHO secretion by polyclonal activation (PWM) of human cord-blood iymphocytes (F. Emmrich, unpublished experiments). Together, both experiments indicate the lack of priming in the newborn, and an acquired state of natural immunity in adults, as corroborated by previous experiments (5) .
In view of the large amounts of anti-A-CHO antibodies in sera, it seemed interesting to evaluate, for comparison, the frequency of specific precursor B cells in PBL after polyclonal activation by PWM. Essentially similar proportions of IgM anti-A-CHO within total IgM were found in serum, SUP of macrocultures, and, by limiting dilution analyses of B cell precursors, in human peripheral blood, the latter amounting to 1/6-1/300 of all IgM-producing B cells. These results suggest a similar distribution of those B cells in lymphoid tissues and in peripheral blood, and also a similar mean IgM production rate when compared with the entire B cell pool.
Using well-established culture conditions, we could induce lymphocytes of some adult individuals to give an A-CHO-specific response. This response is somewhat erratic, and shows large variations between identical culture wells, which, in our hands, is not the case for in vitro secondary responses to tetanus toxoid (a model for a soluble protein antigen). This suggests rather limited requirements for the induction of an anti-A-CHO response that are not only dependent on the number of available precursor B cells (see donor BMR, Table  II and Fig. 3 ). At high vaccine concentration (>106 Strep A cells/culture), diminished specific IgM anti-A-CHO levels were observed. This phenomenon was not due to absorption of the anti-A-CHO by large amounts of streptococci (see comment to Table IV) , and may therefore reflect a specific suppression that is also observed in secondary in vitro responses to high antigen doses of soluble protein antigens (34, 35) . Taken together, we think that not all of the regulatory factors that influence a specific anti-A-CHO response in vitro are sufficiently understood.
In PBL obtained from Strep A-immunized rabbits, IgM anti-A-CHO, as well as IgG anti-A-CHO, plaque-forming cells were induced in an in vitro secondary response, with the latter reaching 83% of the antigen-specificplaques after 15 d of culture (36) . Concomitant secretion of IgG anti-A-CHO into the culture medium was shown. In contrast, we found nearly exclusively anti-A-CHO of the IgM isotype, in both antigen-activated or mitogen-activated human PBL cultures. Although slightly less IgG-secreting B cells are activated in vitro than expected from the IgM/IgG isotype proportion in serum (see Table I ), total IgG in polyclonally activated cultures amounts to nearly the same as total IgM. There-fore, the selective lack of IgG anti-A-CHO in vitro may suggest distinct differentiation requirements for anti-A-CHO-producing B cells compared with those B cell species which readily produce IgG in vitro.
As an alternative, instead of lacking in vitro differentiation, anti-A-CHO IgGproducing B cells are, perhaps, sequestered in certain lymphoid tissues. If this is the correct explanation of our results, we would have to conclude again that the switch from IgM to IgG production does not occur with human PBL under our culture conditions. Indeed, with two different polyclonal activators (PWM and Epstein-Barr virus) as well as with antigenic stimulation of human PBL, virtually no or very rare switch events from IgM to IgG could be demonstrated in vitro (25, 37) . This is in sharp contrast to similar experiments in lipopolysaccharidestimulated murine spleen cells (38) . As discussed by Yarchoan et al. (25) , either an intrinsic difference between human and murine B cells or a difference between peripheral blood B cells and those of other lymphoid organs might explain the results. Preliminary results with polyclonally activated human spleen cells and with tonsilar lymphocytes showed only slightly increased levels of anti-A-CHO IgG (F. Emmrich, unpublished data).
In the control cultures of donor CMR (data not shown) without mitogen or streptococcal antigen, the IgM anti-A-CHO ratio (0.33%) was far less than in both antigen-activated (21.3 %) or PWM-activated cultures (10.3 %, see Table I ). This indicates preferential antibody production in the control cultures by nonanti-A-CHO B cells either preactivated in vivo or stimulated by FCS components in vitro. As demonstrated in Table III , low IgM anti-A-CHO proportions could be elevated by either antigen activation, mitogen activation, or even by increasing the cell density. By these procedures, IgM anti-A-CHO proportions of ~15% were reached, which are equal to the precursor frequency of polyclonally activated B cells, as well as to the IgM anti-A-CHO proportion in serum of donor MSS. Together with the other features mentioned above, this finding may argue for distinct activation requirements of IgM anti-A-CHO B cells, compared with other B cells. A similar situation has previously been described for mice: unresponsiveness to polysaccharide antigens, determined by the xid gene (39) , is associated with the lack of a B cell subpopulation bearing the Lyb-5 marker (40), as well as depressed IgM and IgG3 levels (41) . Lyb-5 + B cells are readily responsive to the combination of antigen and soluble helper factors, whereas Lyb-5-cells require an MHC-restricted interaction with helper T cells (42) . Hence, human B cells with specificity to A-CHO may be useful for the characterization of a similar human B cell subpopulation.
Summary
The immune response to the group-specific carbohydrate of group A streptococci (A-CHO) provides an informative in vitro model for the investigation of several aspects of human anticarbohydrate immune responses. A-CHO-specific B cells can be polyclonally activated by pokeweed mitogen (PWM), and, specifically, by in vitro immunization with streptococcal vaccine. High levels of A-CHO-specific antibodies, mainly directed to the immunodominant side chain Nacetyl-D-glucosamine (GIcNAc), occur in healthy adult individuals. Serum antibody levels are reflected in high frequencies of precursor B cells among periph-eral blood lymphocytes. In one particular case, >15% of all B cells activated by PWM for IgM production were found to produce IgM anti-A-CHO antibodies, as determined in limiting dilution experiments, as well as by analyzing Ig concentrations in bulk culture experiments. The case with the lowest proportion observed had 0.3% A-CHO-specific B cells among IgM-producing B cells. Preferential PWM activation of anti-A-CHO-producing B cells could be excluded.
The comparison of the proportions of anti-A-CHO IgM produced in vivo, and of B cells producing antibodies of this specificity in peripheral blood, suggests a similar distribution of specific precursor B cells in the antibody-producing lymphoid tissue compartments and in peripheral blood. However, nearly all specific antibodies produced in vitro belong to the IgM isotype, whereas IgG anti-A-CHO in high amounts, mostly exceeding the specific IgM, was found only among anti-A-CHO antibodies produced in vivo. Low anti-A-CHO IgG production was seen in polyclonally activated as well as in antigen-activated cultures, whereas, in contrast, total IgG was produced in considerable amounts after polyclonal activation. This suggests a different distribution pattern, and]or diverse differentiation requirements for anti-A-CHO-producing B cells, compared with other B cell species.
